This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Vaccinex | |
|---|---|
| Name | Vaccinex |
| Type | Public |
| Industry | Biotechnology |
| Founded | 2000 |
| Headquarters | Rochester, New York |
| Key people | Mark A. Goldstein; Donald L. Craft; John Scott |
| Products | Monoclonal antibodies; peptide therapeutics; oncology immunotherapies |
Vaccinex is an American biotechnology company focused on developing targeted immunotherapies and antibody-based therapeutics for oncology and neurology. Founded in 2000, the company concentrates on monoclonal antibodies, peptide vaccines, and receptor-targeted agents designed to modulate immune signaling in cancer and neurodegenerative diseases. Vaccinex has pursued clinical programs through partnerships with academic centers, contract research organizations, and pharmaceutical firms while engaging with regulatory authorities in multiple jurisdictions.
Vaccinex was founded in 2000 in Rochester, New York, during a period of rapid expansion in biotechnology alongside firms such as Genentech, Amgen, and Biogen. Early leadership included executives and scientists with ties to institutions like the University of Rochester and collaborations with laboratories at Rochester Institute of Technology and Cornell University. The company grew through the 2000s with seed financing from venture capital firms similar to Sequoia Capital and New Enterprise Associates and pursued discovery programs in immuno-oncology analogous to those at Harvard Medical School and Dana-Farber Cancer Institute. In the 2010s Vaccinex transitioned toward clinical development, filing investigational new drug applications with the U.S. Food and Drug Administration and engaging with regulatory frameworks in the European Medicines Agency and other national agencies. Throughout its history, Vaccinex has navigated market events affecting peers such as Gilead Sciences, Bristol-Myers Squibb, and Roche.
Vaccinex’s corporate governance reflects common practices in public biotechnology companies listed on exchanges akin to the NASDAQ and overseen by regulatory filers subject to Securities and Exchange Commission rules. The board of directors has included executives with backgrounds at firms like Eli Lilly and Company, Pfizer, and Johnson & Johnson, and academic leaders affiliated with Columbia University and Johns Hopkins University. Senior management teams have historically recruited from corporations such as Merck & Co. and Novartis and consulted with advisory boards featuring physician-investigators from Memorial Sloan Kettering Cancer Center, Cleveland Clinic, and Mayo Clinic. Corporate decisions have been influenced by investors including institutional firms comparable to BlackRock and Vanguard Group.
Vaccinex’s R&D model emphasizes antibody engineering, peptide vaccine design, and receptor modulators. The company’s scientific programs draw on methodologies developed at research centers such as MIT, Stanford University School of Medicine, and the Scripps Research Institute. Preclinical studies have used animal models common to translational oncology research, including murine models standardized by laboratories at Cold Spring Harbor Laboratory and techniques adopted from immunology groups at University of California, San Francisco. Collaborations with contract research organizations like Charles River Laboratories and ICON plc support pharmacology and toxicology studies. Vaccinex’s R&D integrates structural biology approaches of the kind advanced at Protein Data Bank contributors and bioinformatics methods used by investigators at Broad Institute and European Bioinformatics Institute.
Vaccinex has developed monoclonal antibodies and peptide-based therapeutics targeting cell-surface receptors and immune checkpoints. Its platforms have conceptual parallels with technologies employed by Regeneron Pharmaceuticals and Moderna in antibody discovery and peptide design, respectively. Therapeutic candidates have focused on oncology indications similar to programs at Celgene and neurodegenerative targets that parallel efforts at Eli Lilly and Axovant Sciences. Manufacturing and process development have been conducted with contract manufacturers akin to Patheon and Lonza Group, and analytical assays follow standards promulgated by organizations such as International Council for Harmonisation.
Vaccinex has initiated multiple clinical trials across phases I–III, registering studies in databases used by sponsors including Pfizer and AstraZeneca. Trial sites have included academic medical centers like University of Pennsylvania Health System, Massachusetts General Hospital, and Johns Hopkins Hospital. Interactions with regulators such as the U.S. Food and Drug Administration and the European Medicines Agency shaped development plans, safety monitoring, and labeling considerations akin to processes experienced by companies like AbbVie and GlaxoSmithKline. Data monitoring committees and institutional review boards from institutions such as Yale School of Medicine and UCLA Health have overseen patient safety in multicenter trials.
Vaccinex has partnered with universities, biopharmaceutical firms, and nonprofit research organizations to advance programs. Academic collaborations have mirrored alliances with Stanford University, Columbia University, and University of California, San Diego investigators. Industry partnerships have been structured similarly to deals between Bayer and small biotech firms, or collaborations like Sanofi with academic consortia. Contract research and manufacturing alliances involve organizations comparable to Parexel International and Thermo Fisher Scientific. Strategic licensing and co-development efforts have involved venture partners and philanthropic research funds resembling those at Wellcome Trust and Bill & Melinda Gates Foundation.
Like many biotechnology companies, Vaccinex has encountered disputes involving intellectual property, contract performance, and shareholder activism. Patent litigation scenarios reflect patterns seen in cases involving Amgen and Gilead Sciences, with contested claims over antibody sequences and manufacturing processes. Contractual disagreements with vendors or collaborators have mirrored disputes in the industry involving firms such as Valeant Pharmaceuticals International and Turing Pharmaceuticals. Shareholder actions, proxy contests, and securities inquiries parallel episodes experienced by public biotechs including Allergan and Theravance Biopharma.